Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
05/05/2026 12:52
May 5 (Reuters) - Sensei Biotherapeutics Inc SNSE.O: SENSEI BIOTHERAPEUTICS DOSES FIRST PATIENT IN PHASE 1B/2 TRIAL OF PIKTOR IN HR+/HER2- ADVANCED BREAST CANCER SENSEI BIOTHERAPEUTICS DOSES FIRST PATIENT IN PHASE 1B/2 TRIAL OF PIKTOR IN HR+/HER2- ADVANCED BREAST CANCER Source text: ID:nBwNM3qwa Further company coverage: SNSE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)